Drugs / labetuzumab
Trials 4
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT00041691 | — | colorectal neoplasm | Gilead Sciences | Terminated | No outcome recorded |
| Phase 1/23 trials | ||||||
| Phase 1/2 | NCT00041652 | Feb 2000 → Jun 2003 | breast cancer, colon carcinoma, rectal cancer | Gilead Sciences | Completed | No outcome recorded |
| Phase 1/2 | NCT00041639 | Jan 2000 → Dec 2003 | malignant pancreatic neoplasm | Gilead Sciences | Completed | No outcome recorded |
| Phase 1/2 | NCT00040599 | Jan 2000 → Jan 2004 | colon carcinoma, rectal cancer | Gilead Sciences | Completed | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 5 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | labetuzumab | “hMN14 (labetuzumab)” NCT00040599 ↗3“hMN14 (labetuzumab)” NCT00041652 ↗ “hMN14 (labetuzumab)” NCT00041691 ↗ “hMN14 (labetuzumab)” NCT00041639 ↗ |
| Known as | hMN14 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT00040599 ↗ |
| Modality | Monoclonal antibody | “Radioimmunotherapy With 90Y-Humanized MN-14 IgG” NCT00040599 ↗ |
| Target | CEACAM5 | “Carcinoembryonic antigen-related cell adhesion molecule 5 other” CHEMBL2108501 ↗ |